SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...

Unity Biotechnology (NASDAQ:UBX) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...

Unity Biotechnology (NASDAQ:UBX) just reported results for the fourth quarter of 2023. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release. The ...

Unity Biotechnology Inc. (UBX) has submitted its 10-K filing for the fiscal year ended December 31, 2024. The filing includes detailed information about the company's financial performance, ...

According to the CDC, the number of Americans aged 65 or older will number nearly 89 million by 2050, or more than double the number of older adults in 2010. Age-associated diseases such as arthritis, ...

Shares of Unity Biotechnology Inc. (NASDAQ:UBX) sank 28.8% to close at $1.30 March 24 as a top-line readout of its phase IIb Aspire study testing UBX-1325 head-to-head against aflibercept in diabetic ...

The data are not enough for Unity Biotechnology to remain committed to the wet age-related macular degeneration indication. (iStock / Getty Images Plus / Rocky89) Patients with wet age-related macular ...